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Novelty and impact 
In this work we describe, for first time, that high activation levels of the TGFβ 
pathway in epithelial ovarian cancers contributes to tumor ovarian cell proliferation 
by stimulating IGF1R expression. Our results have been obtained using orthotopic 
models of these tumors, human patient samples and ovarian tumoral cells, and 
lead us to propose the use of TGFβ inhibitors as an alternative to the use of IGF1R 
inhibitors for the treatment of epithelial ovarian cancers.  
 
The authors declare no conflicts of interest. 
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In a search for new therapeutic targets for treating epithelial ovarian cancer we 
analyzed the Transforming Growth Factor Beta (TGFβ) signaling pathway in these 
tumors. Using a TMA with patient samples we found high Smad2 phosphorylation 
in ovarian cancer tumoral cells, independently of tumor subtype (high-grade serous 
or endometrioid). To evaluate the impact of TGFβ receptor inhibition on tumoral 
growth, we used different models of human ovarian cancer orthotopically grown in 
nude mice (OVAs). Treatment with a TGFβRI&II dual inhibitor, LY2109761, caused 
a significant reduction in tumor size in all these models, affecting cell proliferation 
rate. We identified Insulin Growth Factor (IGF)1 receptor as the signal positively 
regulated by TGFβ implicated in ovarian tumor cell proliferation. Inhibition of IGF1R 
activity by treatment with a blocker antibody (IMC-A12) or with a tyrosine kinase 
inhibitor (linsitinib) inhibited ovarian tumoral growth in vivo. When IGF1R levels 
were decreased by shRNA treatment, LY2109761 lost its capacity to block tumoral 
ovarian cell proliferation. At the molecular level TGFβ induced mRNA IGF1R 
levels. Overall, our results suggest an important role for the TGFβ signaling 
pathway in ovarian tumor cell growth through the control of IGF1R signaling 
pathway. Moreover, it identifies anti-TGFβ inhibitors as being of potential use in 
new therapies for ovarian cancer patients as an alternative to IGF1R inhibition.
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Ovarian cancer is the second most common gynecological cancer by 
incidence (≈6 per 100,000 individuals) and the fifth most common cause of cancer 
death in women in western countries 1. More than 90% of ovarian tumors have an 
epithelial origin and can be classified into four main histological types: high-grade 
serous (70% of cases; the more aggressive type), endometrioid, mucinous and 
clear cell tumors 2. Although progress has been made in the treatment of this 
cancer by improved surgical debulking and the introduction of platinum-taxane 
regimens of chemotherapy, the overall 5-year survival rate is only 29% in 
advanced-stage disease (80% of cases). This low survival rate is mainly because 
of intrinsic and acquired resistance to platinum-based chemotherapy 1,3. Together, 
these observations highlight the importance of having a more detailed 
understanding of potential new targets. 
A good candidate is the Transforming Growth Factor Beta (TGFβ) signaling 
pathway. TGFβs members (formed by TGFβ1, 2 and 3) signal through binding to 
their membrane serine/threonine kinase receptors TGFβRII and I, phosphorylation 
of intracellular effectors Smad2 and Smad3, formation of heterodimers 
phosphoSmad2/3 with Smad4, translocation to the nucleus and regulation of gene 
transcription 4, 5. TGFβ members play a role as inhibitors of normal epithelial and 
endothelial cell proliferation, but they contribute to cancer progression in later 
stages. This dual role is caused by mutations that abrogate the normal cell cycle 
arrest caused by TGFβ members, but that maintain TGFβ−stimulation of the 
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processes involved in cancer progression and dissemination, such as EMT 
transition, angiogenesis, extracellular matrix remodeling, migration and invasion 6-8. 
TGFβ plays a similar role in ovary. Thus, while TGFβ blocks cell growth in normal 
ovarian epithelial cells, in 40% of ovarian carcinomas TGFβ loses its cytostatic 
effect but maintains EMT induction and production of extracellular matrix 9. 
Considering these data from ovarian cancer cells and that treatments against 
TGFβ are now under clinical development 10-12, we decided in this work to study 
the contribution of TGFβ to ovarian cancer progression using orthotopic models of 
ovarian cancer. 
 
MATERIALS AND METHODS 
Chemical compounds 
LY2109761 was kindly provided by Lilly and Co. It was dissolved in 1% 
carboxymethylcellulose-0.5% sodium lauryl sulfate (Sigma)-0.085% 
Polyvinylpyrrolidone (Sigma)-0.05% antifoam (Sigma) solution. Drug aliquots were 
prepared every two weeks and kept in the dark at 4°C. IMC-A12 (Cixutumumab) 
was obtained from ImClone (NJ, USA). Linsitinib was obtained from LC 
Laboratories (MA, USA) and was dissolved in 25 mM tartaric acid (Sigma) solution. 
TGFβ was provided by R&D. Other reagents were purchased from Sigma or 
Roche. 
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Orthotopic implantation of ovarian tumors 
Female NMRI-nu immunodeficient mice (strain NMRI-Foxn1nu/Foxn1nu) were 
purchased from Janvier (France). Mice were housed and maintained in laminar 
flow cabinets under specific pathogen-free conditions. All the animal studies were 
approved by the local committee for animal care (DAAM 5766). 
The ovarian tumors used were perpetuated in nude mice by consecutive passages. 
We used three orthotopic ovarian patient-derived xenograft (PDX, also called 
Orthoxenografts) models. They were generated in our group by implantation into 
nude mice of tumor samples obtained from untreated patients after surgery. The 
study protocol was cleared by Ethics Committee of Bellvitge Hospital and a signed 
informed consent was obtained from each patient. PDX were one endometrioid 
tumor model (OVA15, from a 72 years old patient, FIGO stage I) and two high-
grade serous ovarian tumor models, OVA8 (from a 47 years old patient, FIGO 
stage III) and OVA17 (from a 77 years old patient, FIGO stage III). At the 
histological level all three patient tumors were grade 3, but clinically (FIGO 
classification) OVA 15 was classified as Stage I while OVA 8 and OVA17 were 
classified as Stage III. At the mutational level, all three tumors present mutations in 
TP53. Moreover, OVA15 presents a mutation in ARID1A, while OVA8 presents a 
heterozygous STOP codon in BRCA2 gene.  
Patient that originated OVA17 already presented a big dissemination node ( > 8 
cm) and 15 para-aortic nodes. When implanted in mice this tumor generates 
macroscopic tumoral nodes in the peritoneal zone and liver metastasis. All the 
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OVA17 implanted in mice developed peritoneal dissemination after two months 
from implantation.  
For surgical implantation mice were anesthetized by isoflurane inhalation. A small 
incision was made and the ovaries were exteriorized. A 6-mm3 piece tumor was 
implanted in each ovary using Prolene 7.0 surgical sutures. The ovaries were 
returned to the abdominal cavity and the incision was closed with wound clips. 
Buprex was administered i.p. to the mice (200 µl) the day of the surgical 
intervention and for two days after the implantation. 
 
Treatment schedule 
As the tumors had different growth behaviors the treatment schedules were 
different. Treatments started when a palpable intra-abdominal mass was detected; 
studies were terminated when tumors in vehicle-treated animals were judged to be 
adversely affecting their wellbeing.  
Treatment of the high-grade serous tumor models OVA8 and OVA17 started 5 
weeks after implantation and continued for one further month. Treatment of the 
OVA15 endometrial model started six weeks after tumor implantation and 
continued for another month more. Mice were treated with LY2109761, 
administered twice daily with gavage as an oral dose of 100 mg/kg 13. Control mice 
were treated with the vehicle oral solution as the treated groups.  
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These treatments had no significant effect on mouse body weight and the animals 
appeared healthy and active throughout the study.  
Linsitinib treatment of OVA8 started 4 weeks after implantation. Linsitinib was 
administered daily (5 days) with an oral dose of 40 mg/kg by gavage 14, 1 week 
without treatment followed by a new cycle of treatment for 5 days. Control mice 
were treated with the vehicle oral solution as the treated groups.  
IMC-A12 (Cixutumumab) treatment of OVA17 started 5 weeks after implantation. 
The antibody was administered i.p. three times a week for 4 weeks at a dose of 12 
mg/kg.  
After sacrifize the effects of the different treatments on tumor response were 
evaluated by determining tumor weight and volume, where volume = 
(length)(width2/2).  
 




To explore the importance of the TGFβ signaling pathway in ovarian cancer, 
we first performed immunohistochemical analysis for active Smad2 levels 
(phosphoSmad2 or pSmad2), instead of using total protein levels. We used a TMA 
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containing 32 high-grade serous and 34 endometrioid primary tumors obtained 
from patients affected by these ovarian cancers. As observed in Fig. 1A, the main 
part of the tumors were stained for pSmad2 at high levels, all of them presenting 
nuclear localization as expected for active pSmad2. No differences in pSmad2 
were found when comparing high-grade serous with endometrioid tumors (Fig. 1B). 
We detected high activation levels of pSmad2 in the epithelium of normal human 
Fallopian tube compared with parenchymal cells (Fig. 1C). These epithelial cells 
are mainly the origin of epithelial high-grade serous tumoral ovarian cells 15, 16, 
indicating that these tumoral cells maintain a pathway that is already active in 
normal physiology. 
 The previous results prompted us to investigate the role of the TGFβ 
pathway for ovarian cancer progression in both tumors subtypes in greater depth. 
To this end we used orthotopic pre-clinical models  generated after implantation in 
nude mice of tumors samples obtained from patients after surgery (PDX or 
orthoxenografts), two high-grade serous ovarian tumors (OVA8 and OVA17) and 
OVA15, an endometrioid ovarian tumor model. We confirmed the results of high 
pSmad2 levels in normal epithelial cells from human samples in those of normal 
mouse Fallopian tube (Fig. 1C). We also observed that the PDX orthotopic models 
presented a high degree of nuclear pSmad2 staining, very similar to the expression 
pattern found in primary tumors (Fig. 1C).  
In order to block activation of the TGFβ pathway in these models we 
measured the effect of an inhibitor of TGFβRI and II kinase activity, LY2109761 17 
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that had previously showed inhibitory effects on ovarian cancer cells 18, on the 
growth of orthotopic ovarian tumors. After tumor implantation, mice bearing these 
tumors were randomized into two groups, and when a palpable intra-abdominal 
mass was detected, animals were treated with the vehicle or LY2109761 for 1 
month. The treatments had no significant effect on mouse body weight and the 
animals appeared healthy and active throughout the study. LY2109761 treatment 
reduced tumor growth in all the tumor models tested (Fig. 2A): OVA17 (tumor 
volume: 1337 mm3 in control versus 537 mm3 in treated), OVA8 (control, 1088 
mm3 versus treated, 583 mm3) and OVA15 (control, 2291 mm3 versus treated, 991 
mm3). The effectiveness of the TGFβ inhibition was verified by western blot of 
tumor samples. A reduction in the levels of pSmad2 after LY2109761 treatment 
was observed in all the tumors treated (Fig. 2B). Surprisingly, the LY2109761 
treatment only inhibited tumor growth; it had no effect on the capacity of the tumor 
to disseminate to other organs (Supplementary Fig. 1A). 
The above results prompted us to determine how LY2109761 reduced 
tumor volume. We focused our study on OVA17 tumor samples as it was the one 
with the most statistically significant reduction in tumour volume. Our results 
showed that tumor size reduction was not due to an increase in apoptosis or 
necrosis (Supplementary Fig. 1B and C), ruling out the possibility of an effect of the 
treatment increasing cell death, or to changes in angiogenesis (Supplementary Fig. 
1D). Subsequently, we examined whether cell proliferation became blocked by 
inhibition of the TGFβ pathway. With this objective, sections of control and treated 
tumor samples from OVA17 were stained with Ki67. LY2109761 treatment caused 
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a significant decrease in the proliferation rate (Fig. 2C). This effect on proliferation 
was also observed in the other tumoral models (OVA8 and OVA15, Fig. 2C). To 
confirm this effect we analyzed several proteins and signaling pathways involved in 
the control of cell proliferation. We did not detect any change in active or total AKT 
levels when comparing samples from control and LY2109761-treated OVA17 
tumors (Fig. 2D and Supplementary Fig. 2A). In contrast, active ERK1/2 levels 
were decreased by 38% with LY2109761 treatment (Fig. 2D and Supplementary 
Fig. 2B). This effect was also observed in OVA8 treated tumors (Supplementary 
Fig. 2B). Next we checked proteins directly involved in cell cycle progression. We 
found no change in p21 or Cyclin A, although an increase in p16 (70%) and in E-
Cadherin (350%) protein levels were noted (Fig. 2E and Supplementary Fig. 2C 
and 2D). In contrast, Cyclin D1 levels (measured by immunohistochemistry) were 
decreased by 60% in tumors treated with LY2109761 (Fig. 2F).  
As the TGFβ signaling pathway by itself is not a classical stimulator of cell 
proliferation, we thought that this effect could be mediated by a different factor that 
is regulated by TGFβ. Equivalent mechanisms have already been described, for 
example in gliomas, in which inhibition of TGFβ reduced the size of tumors by 
affecting PDGF-B production and PDGFRβ-signaling pathways19. To establish 
whether this was also the case in ovarian tumors, we checked the expression of 
members of the PDGF family (PDGF-A, PDGF-B, PDGFRα and PDGFRβ) at the 
mRNA level, but found no difference between the groups (Supplementary Fig. 3A-
D). Some other receptors from proliferation pathways like HER/ERBR family 
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compartments (Fig. 3C). We used our TMA containing samples from various 
patients affected by ovarian cancers to analyze IGF1R expression. As seen in Fig. 
3D, and similarly to the pSmad2 staining, the main part of the tumors presented 
high levels of IGF1R. More strikingly, we found a significant correlation between 
the levels of pSmad2 and IGF1R in the same serous tumor (Fig. 3E). These results 
indicate that IGF1R expression is dependent on the activation of the TGFβ-Smad2 
pathway. 
Next, we decided to study the importance of IGF1R in our ovarian tumor 
cancer models. To this end, we treated OVA17 tumors with IMC-A12 
(Cixutumumab), a monoclonal antibody against IGF1R that blocks the activity of 
this receptor. Treatment for 4 weeks with this antibody caused an 8% decrease in 
body weight of the animals. Given these side effects, antibody treatment caused a 
42% decrease in tumor size (control tumors, 1225 mm3 versus treated tumors, 713 
mm3) (Fig. 4A), indicating the great importance of this signaling pathway in this 
ovarian cancer model. We also tested linsitinib (OSI-906), a tyrosine kinase 
inhibitor specific for IGF1R and insulin receptor 14, 22 on OVA8 growth. In this case 
we also observed side effects on mice body growth (14% decrease after 1 week of 
treatment). For this reason, we administer linsitinib in an alternating regimen of two 
cycles of 5 days treatment followed by 7 days off. In all, animals were treated or 
not with linsitinib for 10 days. At the end of the treatment, treated animals 
presented a 14% decrease in body weight. Even considering these toxic effects, 
however, linsitinib caused a 60% decrease in tumor volume (controls, 1500 mm3 
versus treated, 600 mm3; Fig. 4B).  
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The question arises as to how the TGFβ pathway affects IGF1R levels. To 
answer this first we measured IGF1R mRNA levels in the various treated and 
untreated orthotopic tumors. As observed in Fig. 5A, LY2109761 treatment caused 
a decrease in IGF1R mRNA levels in OVA8 and OVA15 tumors, while no effect 
was observed in OVA17, implying that several TGFβ-stimulated mechanisms 
control IGF1R levels. Next, we used cell culture ovarian tumoral models to analyze 
for IGF1R expression and TGFβ stimulation. Of the cell lines analyzed, the A2780 
and OV90 ovarian serous cell types responded well to TGFβ stimulating Smad3 
phosphorylation, effect that was inhibited by LY2109761 (Fig. 5B and 
Supplementary Fig. 4A). We evaluated in these cells the effect of LY2109761 
inhibitor on cell viability. Addition of LY2109761 caused a dose-response inhibition 
in the number of viable cells (Fig. 5C and Supplementary Fig. 4B). We also 
incubated cells in the presence of IMC-A12 antibody. Results also indicated a 
reduction in cell viability caused by IMC-A12 incubation, similar results to the 
obtained in tumors. We measured IGF1Rβ protein levels in A2780 cells treated for 
24 h with TGFβ or LY2109761. TGFβ caused a 100% increase in IGF1Rβ levels, 
while LY2109761 treatment caused a 23% decrease in this protein (Fig. 5D). 
Analysis of mRNA expression of members of the IGFs signaling pathway (e.g., 
IGF1, IGF1R and IGF1 binding proteins) revealed a TGFβ stimulation and 
LY2109761 inhibition of IGF1R mRNA levels in A2780 cells (Fig. 5E). Overall, 
these results suggest a transcriptional mechanism involved in controlling IGF1R 
levels, which is consistent with the results obtained from OVA8 and OVA15 
orthotopic tumor models.  
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A further question arises as to how important IGF1R is in the observed 
LY2109761-effect. To address this issue, we inhibited IGF1R expression in A2780 
and OV90 cells. By transducing lentiviral vectors expressing either IGF1R-shRNAs 
or a negative control using a non-silencing vector, A2780- or OV90-NS and A2780- 
or OV90-shIGF1R cells were generated. We used three independent shRNA 
vectors. Two of them (shV2-71 and shV2-72) reduced IGF1Rβ protein expression 
by 70-90% (Fig. 6A and Supplementary Fig. 4C), while the shV2-48 vector only 
reduced expression by 30%. This IGF1Rβ protein depletion caused a reduction in 
pERK1/2 levels (Fig. 6A and Supplementary Fig. 4C). As shown in Fig. 6B, the 
decrease of IGF1Rβ levels in A2780 cells reduced cell number in proportion to the 
IGF1Rβ levels still expressed: 70% inhibition in shV2-71 and shV2-72, but no 
reduction in shV2-48. In order to determine whether the LY2109761 effect was 
IGF1R-dependent, we added LY2109761 inhibitor to A2780-NS cells and to 
A2780-shIGF1R cells. Inhibition of IGF1Rβ expression caused a loss of 
LY2109761 sensitivity (Fig. 6C), indicating that IGF1R expression was critical for 
the LY2109761 effect. The same results were obtained in OV90 cells 
(Supplementary Fig. 4D). 
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Our results show that TGFβ plays an important role in proliferation of 
epithelial ovarian tumoral cells through the positive regulation of IGF1R protein 
levels. An active TGFβ signaling pathway is characteristic of later stages of tumoral 
proliferation, as in squamous cell carcinomas23 or gliomas19. In these latter tumors, 
high pSmad2 is correlated with poor prognosis. For this reason, different targeted 
drugs have been developed against this pathway, some of which are currently in 
clinical trials 10-12. It has recently been described that in advanced serous ovarian 
cancers pSmad2 staining is also correlated with poor patient outcome 24. Our 
results confirmed the activation of the canonical TGFβ signaling pathway (high 
Smad2 phosphorylation) on ovarian carcinomas and with independence of their 
anatomical origin (high-grade serous or endometrioid). PSmad2 is present in 
tumoral cells, with only a few positive stromal cells. Our results also indicate that 
ovarian epithelial tumors maintain the activity of the TGFβ-Smad2/3 pathway, 
which is already active in normal Fallopian tube epithelium. In fact, this pathway 
also plays a positive role for granulosa cell proliferation during normal ovarian 
physiology 25, 26.  
Our results suggest that IGF1R mediates the TGFβ effects on proliferation in 
ovarian cancer cells. IGF1R, a member of the insulin superfamily of growth 
promoting factors, has been implicated in the progression of many tumors 
controlling cell growth and proliferation 27, 28. This TGFβ-IGF1R link is supported by 
the observed correlation between pSmad2 and total IGF1R levels in our orthotopic 
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models and in the TMA analyzed here. Control of IGF1R levels by TGFβ includes 
control of its mRNA levels probably through transcriptional mechanisms involving 
Smads, given that Smad binding sites are present in the conserved promoter 
region of the human IGF1R gene. Our results also identify that in OVA17 tumor 
IGF1R mRNA is not affected by TGFβ, implicating alternative post-translational 
mechanisms. However, the important point is that TGFβ always positively controls 
IGF1R levels in ovarian cancer cells. Positive effects of TGFβ on the IGF1R 
pathway have been described in osteosarcoma cells, where TGFβ increases 
IGFBP-3 protein, in turn boosting IGF1R signaling 29. In normal prostate cells the 
IGF axis and TGFβ are both upregulated during normal prostate epithelial 
differentiation, and downregulated in local prostate cancer. After TGFβ treatment, 
the expression of the IGF axis was enhanced in prostate cells expressing TGFβ 
receptors 30. But to our knowledge, this is one of the first times that TGFβ has been 
shown to directly control IGF1R protein levels in tumoral cells. However, similar 
indirect mechanisms of control of cell growth and proliferation by TGFβ through 
other growth factors have been described, for example, in glioma models, where 
TGFβ stimulates production of PDGF-B and activation of PDGFRβ 19. 
As indicated, IGF1R plays a role in the progression of various cancers, 
including those of the ovary 27,28. For this reason, several clinical trials are 
evaluating the effect of IGF1R inhibitors in different tumors, including ovarian 
cancers. Some clinical trials have given modest results and some of these 
inhibitors proved to be toxic. We obtained the same result in our mouse 
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experiments treating animals with inhibitors against IGF1R, the blocking antibody 
IMC-A12 (Cixutumumab) and linsitinib (OSI-906), an inhibitor of the tyrosine kinase 
of the insulin and IGF1 receptors. Both treatments decreased mouse weight by 8-
14%. Taking these unwanted effects into account, our results indicate that TGFβ 
inhibitors could be considered to be a treatment that is less toxic while producing 
similar anti-tumoral effects, at least in ovarian carcinomas. Over all, our results 
indicate that inhibitors of the TGFβ pathway could be a therapeutic alternative for 
the treatment of ovarian tumors in which the IGF1R plays a key role. 
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Figure 1. Epithelial ovarian tumors present high levels of pSmad2.  
A) Examples representative of low (a), moderate (b) and high (c) levels of positive 
pSmad2 immunostaining in ovarian cancer patient samples.  
B) Quantification of pSmad2 levels (using the multiplicative index of the stain 
intensity and the labeling frequency) in tumor tissue sections from high-grade 
serous or endometrioid tumor patients. Data analyzed from 66 tumor patients.  
C) Hematoxylin-eosin (c, d, g and h), pSmad2 (a, b, e, f, i and j) staining of normal 
Fallopian tube epithelium (human, a or mouse, b), the original human tumor biopsy 
(c, e, g and i), OVA17 (d and f) and OVA15 (h and j) orthotopic tumors. a-j 400x, 
bar 100 µm. K and L amplifications at 630x of f and j, bar 20 µm. 
 
Figure 2. Blocking of TGFβR activity inhibits tumor growth in three xenograft 
orthotopic models of epithelial ovarian tumors 
A) Mice with orthotopically implanted OVA15, OVA8 or OVA17 ovarian tumors 
were treated with vehicle (5, 6 and 9 mice, respectively) or twice daily with 100 
mg/kg LY2109761 (4, 6 and 9 mice, respectively) for four weeks. Mice were 
sacrificed when control mouse tumors affected the wellbeing of the animals. Final 
volumes are illustrated by a boxplot. *, p < 0.05; **, p < 0.01 (two-tailed Mann-
Whitney U test). 
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B) Expression of pSmad2 and tubulin were analyzed by western blot in 
LY2109761-treated and control tumors. A representative blot showing results 
obtained for 3 independent OVA15 control tumors and 3 independent OVA15 
LY2109761-treated tumors is shown. Densitometric quantifications of 
phosphoSmad2 relative to tubulin are shown. Results are the mean ± SEM of 5 
controls and 6 LY-treated tumors in OVA15, 4 controls and 6 treated for OVA8 and 
4 control tumors and 3 LY2109761-treated tumors in OVA17. Results are 
presented in arbitrary units relative to the control group. ∗, p < 0.05 (Mann-Whitney 
U test). 
C) Sections from control and treated OVA15, OVA 8 and OVA17 tumors were 
stained for the proliferation marker Ki67. Quantification of the percentage of tumor 
Ki67-positive cells is shown. Results are the mean ± SEM of 4 controls and 3 LY-
treated tumors in OVA15, 6 controls and 6 treated for OVA8 and 4 control tumors 
and 8 LY2109761-treated tumors in OVA17. **, p < 0.01 (two-tailed Mann-Whitney 
U test).  
D) Expression of phosphorylated AKT (p-AKT), total AKT, phosphorylated ERK1/2 
(p-ERK1/2), total ERK1/2 and tubulin was analyzed by western blot in OVA17 
LY2109761-treated and control tumors. A representative blot showing results from 
two independent control tumors and four independent LY2109761-treated tumors.  
E) Expression of E-cadherin, Cyclin A, p21, p16 and tubulin was analyzed by 
western blot in OVA17 LY2109761-treated and control tumors. A representative 
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blot showing results from 2 independent control tumors and 2 independent 
LY2109761-treated tumors is shown.  
F) Sections from OVA17 control and treated tumors were stained for cyclin D1. 
Quantification of tumor cyclin D1-positive cells is expressed relative to the control 
group. Results are the mean ± SEM of 3 controls and 5 LY2109761-treated 
tumors. *, p < 0.05 (two-tailed Mann-Whitney U test). 
 
Figure 3. IGF1R protein levels decrease after LY2109761 treatment  
A) Phosphorylation levels of various RTKs were analyzed using a human phospho-
RTK array kit in LY2109761-treated and control OVA17 tumors. Results are the 
mean of 2 control tumors and 2 LY2109761-treated tumors, and are represented in 
arbitrary units (after densitometric quantification) relative to the control group. 
B) Total IGF1Rβ and vinculin expression was analyzed by western blotting in 
independent OVA17, OVA8 and OVA15 tumors from the treatments with vehicle or 
LY2109761. Representative blots show the results obtained. Densitometric 
quantifications of IGF1Rβ relative to vinculin are shown. Results are the mean ± 
SEM of 4 control tumors and 4 LY2109761-treated tumors in OVA17 (∗, p < 0.05, 
two-tailed Mann-Whitney U test), 3 controls and 3 treated for OVA8 (∗, p < 0.05, T-
test) and 4 controls and 3 LY-treated tumors in OVA15. Results are presented in 
arbitrary units relative to the control group.  
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C) Histological IGF1R staining of OVA17 orthotopic tumors. Total (top) or 
membrane localized (down, indicated with arrows) 400x, bar 100 µm. 
Quantification of IGF1R total levels (top) or present in membrane (bottom) in tumor 
tissue sections from OVA17 control or LY2109761-treated samples. Results are 
the mean ± SEM of from 6 controls and 7 treated samples. ∗, p < 0.05, two-tailed 
Mann-Whitney U test. 
D) Quantification of IGF1R levels (using the multiplicative index of the intensity of 
the stain and the labeling frequency) in tumor tissue sections from high-grade 
serous or endometrioid tumor patients. Data are from 65 tumor patients.  
E) Correlation between pSmad2 and total IGF1R levels in tissue microarray from 
high-grade serous ovarian patients analyzed in Fig. 1B and Fig. 4D. The Spearman 
correlation coefficient is shown.  
 
Figure 4. Blocking IGF1R activity inhibits tumor growth  
A) Mice with an orthotopically implanted OVA17 tumor were treated with vehicle (6 
mice) or the antibody IMC-A12 i.p. three times a week for 4 weeks at a dose of 12 
mg/kg (4 mice). Mice were sacrificed when control mouse tumors affected the 
wellbeing of the animals. Final volumes are illustrated by a boxplot.  
B) Mice with an orthotopically implanted OVA8 tumor were treated with linsitinib 
with an oral dose of 40 mg/kg by gavage (as indicated in results) to six mice. Eight 
mice were treated with the vehicle orally. Mice were sacrificed when control mouse 
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tumors affected the wellbeing of the animals. Final volumes are illustrated by a 
boxplot. *, p < 0.05 (Mann-Whitney U test). 
 
Figure 5. TGFβ stimulates IGF1R mRNA and protein  
A) mRNA levels of human IGF1R analyzed by quantitative real-time PCR in 
OVA17 (4 control tumors and 5 LY2109761-treated tumors), OVA8 (4 control and 3 
LY-treated tumors samples) and OVA15 (5 control tumors and 3 LY2109761-
treated tumors) orthotopic ovarian tumors. Results are expressed as the mean and 
SEM of mRNA expression relative to the control group. *, p < 0.05 (Mann-Whitney 
U test). 
B) Exponential A2780 cells were incubated for 30 min in the absence (DMSO) or 
presence of TGFβ or TGFβ and 2 µM LY2109761. Cells were lysed and 
phosphoSmad3, total Smad2/3 and β-Actin expression was analyzed by western 
blot. A blot representative of three independent experiments is shown.  
C) A2780 cells incubated for 5 days in the presence of the indicated concentrations 
of LY2109761, 50 µg/ml IMC-A12 or in the absence (DMSO). Cell viability was 
measured by MTT assay. Results are expressed relative to the control condition. 
Each data point represents the mean and SEM of five independent determinations. 
Differences between control and treated cases were considered statistically 
significant when p < 0.05 (*) or p < 0.01 (**) (two-tailed Mann-Whitney U test).  
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D) Expression of IGF1Rβ and β-Actin, as a loading control, were analyzed by 
western blot of A2780 cells lysates. Cells were incubated for 24 h with DMSO, 
TGFβ1 (10 ng/ml) or LY2109761 (2 µM). A representative blot of the results is 
shown. 
E) mRNA levels of human IGF1R, IGF2R, IGF1 and IGF2 were analyzed by 
quantitative real-time PCR in A2780 (4 samples) cells incubated for 8 or 24 h with 
DMSO, TGFβ1 (10 ng/ml) or LY2109761 (2 µM). Results are expressed as the 
mean and SEM of mRNA expression relative to control condition. *, p < 0.05 (two-
tailed Mann-Whitney U test). 
 
Figure 6. IGF1R mediates LY2109761 effect.  
A) IGF1Rβ, phosphorylated ERK1/2 (pERK1/2), total ERK1/2 and tubulin protein 
levels were analyzed by western blot in A2780-sh-NS, A2780-sh71, A2780-sh72 or 
A2780-sh48 cell lysates. A blot representative of three independent experiments is 
shown. 
B) 5000 A2780-sh-NS, A2780-sh71, A2780-sh72 or A2780-sh48 cells were 
incubated for 3 days in normal medium, trypsinized and the number of cells was 
counted. Each data point represents the mean and SEM of 3 independent 
determinations. p < 0.05 (*) (T-test). 
C) A2780-sh-NS, A2780-sh71, A2780-sh72 or A2780-sh48 cells were incubated 
for 5 days in the presence of the indicated concentrations of LY2109761 or in the 
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absence (DMSO). Cell viability was measured by MTT assay. Results are 
expressed as percentage relative to the control condition. Each data point 
represents the mean and SEM of three independent determinations. *, p < 0.05 




Page 28 of 34
John Wiley & Sons, Inc.





Figure 1  
210x297mm (300 x 300 DPI)  
 
 
Page 29 of 34
John Wiley & Sons, Inc.





Figure 2  
210x297mm (300 x 300 DPI)  
 
 
Page 30 of 34
John Wiley & Sons, Inc.





Figure 3  
210x297mm (300 x 300 DPI)  
 
 
Page 31 of 34
John Wiley & Sons, Inc.





Figure 4  
210x297mm (300 x 300 DPI)  
 
 
Page 32 of 34
John Wiley & Sons, Inc.





Figure 5  
209x297mm (300 x 300 DPI)  
 
 
Page 33 of 34
John Wiley & Sons, Inc.





Figure 6  
209x297mm (300 x 300 DPI)  
 
 
Page 34 of 34
John Wiley & Sons, Inc.
International Journal of Cancer
